“Personalized” battle against GI cancers: ASCO GI 2024 highlights
Personalized medicine is revolutionizing the field of oncology, and gastrointestinal (GI) cancers are at the forefront. While immunotherapy has made a transformational impact in many areas, it hasn’t seen the same success in GI cancers. This has led to rising recognition of cancer heterogeneity and highlighting the need for personalization for therapeutic benefit in subpopulations.
The key highlights at ASCO GI 2024 resonated with the theme of ‘Taking Personalized Care to the Next Level’ and provided a glimpse into the future of personalized medicine for GI cancers. Discover the post-conference takeaways from Inizio Advisory here.
Here’s how we help to shape the future of oncology treatments.
Jump to a slide with the slide dots.
Driving impact and innovation: Key insights from MAPS EMEA 2025
Across spotlight sessions, workshops, and conversations, three core themes stood out. Read about them in our latest article.
Read moreExpert perspectives live
from ASCO® 2025
Three of our experts sat down with OncoDaily to share their unique perspectives in oncology.
Read moreTransforming oncology: Five frontiers driving progress in cancer care
Discover five key frontiers reshaping oncology, from biomarker breakthroughs and ctDNA diagnostics to ADC innovations, early intervention, and true..
Read more